Skip to main content
OpenTrials
Completed

NCT Number: NCT01965613

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pyoderma Gangrenosum Pyoderma Skin Diseases Skin Diseases, Vascular Skin Ulcer Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

XBiotech Investigative Site

Tallahassee, Florida, 32308, United States

About this study

XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥18
  • History of pyoderma gangrenosum with or without other systemic disease.

Exclusion criteria

  • Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer).
  • Treatment with corticosteroids or cyclosporine within the last 2 weeks.

Treatment and study plan

Xilonix

Biological

IV

Primary outcomes

  1. Change in Physician's Wound Assessment & Patient's Global Assessment

    Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Janssen Research & Development, LLC

Industry

Registry information

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 18, 2013
Registry last updated
Jul 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.